FDA approves oral therapy for Grade 2 IDH-mutant glioma
Drug Discovery World
AUGUST 8, 2024
The US Food and Drug Administration (FDA) has approved Voranigo, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated for the treatment of patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma.
Let's personalize your content